ClinicalTrials.gg
Active, not recruitingNCT04270409Updated Dec 12, 2025

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

A Phase 3 interventional study of Isatuximab SAR650984 and Lenalidomide in Plasma Cell Myeloma, sponsored by Sanofi. Active, not recruiting at 105 sites in 24 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
337
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing isatuximab in Multiple Myeloma — 15 open to participants now, 34 under way, 9 of them phase 3. isatuximab · Multiple Myeloma.

Enrollment
8th of 50
337 · median 55
Started
2020
with 2 others
Phase 3
9 of 50
1 open now
Primary completion
2030-10
later than 30 of 33 live
Registered
16th of 50
by date
Lead sponsor
13 of 50
Sanofi

Among the 50 studies testing isatuximab in Multiple Myeloma, this one is the 8th largest by enrollment, is one of 3 that started in 2020, is one of 9 in phase 3, reaches primary completion later than 30 of the 33 other live ones, and was the 16th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 50 studies testing isatuximab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About isatuximab

isatuximab: first FDA approval 2020 (SARCLISA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing isatuximab in Multiple Myeloma, or all of them as a file.
02

Study summary

Primary Objectives:

  • Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)
  • Randomized Phase 3 Part: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to lenalidomide and dexamethasone in subjects with high-risk SMM

Secondary Objectives:

Safety run-in Part:

  • To assess overall response rate (ORR)
  • To assess duration of response (DOR)
  • To assess minimal residual disease (MRD) negativity in participants achieving very good partial response (VGPR) or complete response (CR)
  • To assess time to diagnostic (SLiM CRAB) progression or death
  • To assess time to first-line treatment for multiple myeloma (MM)
  • To assess the potential immunogenicity of isatuximab
  • Impact of abnormal chromosomal subtype on participant outcome

Randomized Phase 3 Part:

Key Secondary Objectives:

To compare between the arms

  • MRD negativity
  • Sustained MRD negativity
  • Second progression-free survival (PFS2)
  • Overall survival

Other Secondary Objectives:

To evaluate in both arms

  • CR rate
  • ORR
  • DOR
  • Time to diagnostic (SLiM CRAB) progression
  • Time to biochemical progression
  • Time to first-line treatment for MM
  • Impact of abnormal chromosomal subtype on participant outcome
  • Safety and tolerability
  • Pharmacokinetics (PK)
  • Potential of isatuximab immunogenicity
  • Clinical outcome assessments (COAs)
Read the detailed description

Study duration is expected to be approximately 12 years, including a 42-day screening period, followed by an up to 36-month treatment period, and a follow-up period of approximately 9 years.

03

Conditions studied

  • Plasma Cell Myeloma

Browse trials for

Keywords

  • Anti-CD38 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are diagnosed within 5 years with SMM (per International Myeloma Working Group [IMWG] criteria), defined as serum M-protein ≥30 g/L or urinary M-protein ≥500 mg per 24 hour or both, and/or clonal bone marrow plasma cells (BMPCs) 10% to \<60%, and absence of myeloma defining events or other related conditions and with high-risk SMM
  • (ECOG) Performance Status 0 or 1 or 2
  • Capable of giving voluntary written
  • (ANC) ≥1000/µL (1 × 10\^9/L)
  • ≥50,000/µL (50 × 10\^9/L)
  • Total ≤3 mg/dL (except Gilbert syndrome, in which direct bilirubin should be -≤5 mg/dL).
  • ≤3× (ULN), aspartate aminotransferase ≤ 3 × ULN.

Exclusion criteria

Exclusion criteria:

  • Evidence of any of the following calcium, renal failure, anemia, bone lesions (CRAB) criteria or Myeloma Defining Events (SLiM CRAB) detailed below (attributable to the participants SMM involvement):

    • Increased calcium levels: Corrected serum calcium >1 mg/dL above the or >11 mg/dL
    • Renal insufficiency: Determined by (GFR) \<40 mL/min/1.73 m² (Modification of Diet in Renal Disease [MDRD] Formula) or serum creatinine >2 mg/dL
    • Anemia ( 2 g/dL below lower limit of normal or \<10 g/dL or both) transfusion support or concurrent treatment with erythropoietin stimulating agents is not permitted
    • ≥ 1 bone lytic lesion
    • BMPCs ≥60%
    • Serum involved/uninvolved FLC ratio ≥100 and an involved FLC ≥100mg/L
    • Whole body magnetic resonance imaging (WB-MRI) or positron emission tomography-computed tomography (PET-CT) with more than 1 bone focal lesion (≥5 mm in diameter by MRI)
  • Primary systemic amyloid light-chain (AL) amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), standard risk smoldering myeloma, soft tissue plasmacytoma, symptomatic myeloma
  • Uncontrolled infection within 28 days prior to randomization in Phase 3 or first study intervention administration in safety run-in
  • cardiac or vascular disease within 3 months prior to randomization, e.g. Myocardial Infarction; Unstable Angina; Coronary (e.g. Coronary Artery Bypass Graft, Percutaneous Coronary Intervention) or peripheral artery revascularization, \<40%, Heart Failure III-IV, Stroke, , Pulmonary Embolism, other thromboembolic event, cardiac arrhythmia (Grade 3 or higher by Version 5.0)
  • Known acquired immunodeficiency syndrome (AIDS)-related illness or known (HIV) disease requiring antiviral treatment or active hepatitis A (defined as positive hepatitis A antigen or positive IgM). HIV serology at screening will be tested for German participants and any other country where required as per local regulations and serology and C at screening will be tested for all participants
  • Uncontrolled or active hepatitis B virus (HBV) infection: Patients with positive Hepatitis B surface antigen (HBsAg) and/or HBV Deoxyribonucleic acid (DNA)

Of note:

  • Patient can be eligible if anti-HBc Immunoglobulin G (IgG) positive (with or without positive anti-HBs) but HBsAg and HBV DNA are negative. If anti-HBV therapy in relation with prior infection was started before initiation of IMP, the anti-HBV therapy and monitoring should continue throughout the study treatment period.
  • Patients with negative HBsAg and positive HBV DNA observed during screening period will be evaluated by a specialist for start of anti-viral treatment: study treatment could be proposed if HBV DNA becomes negative and all the other study criteria are still met.
  • Active virus (HCV) infection: positive HCV ribonucleic acid (RNA) and negative anti-HCV

Of note:

  • Patients with antiviral therapy for HCV started before initiation of IMP and positive HCV antibodies are eligible. The antiviral therapy for HCV should continue throughout the treatment period until seroconversion.
  • Patients with positive anti-HCV and undetectable HCV RNA without antiviral therapy for HCV are eligible
  • Malabsorption syndrome or any condition that can significantly impact the absorption of lenalidomide
  • Any of the following within 3 months prior to randomization (or first study intervention administration in safety run-in cohort): treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event
  • Received treatment (eg surgery, radiotherapy, medication) for a within 3 years of randomization (or first study intervention administration in safety run-in cohort)
  • Prior exposure to approved or treatments for SMM or multiple myeloma (MM) (including but not limited to conventional chemotherapies, immunomodulatory imid drugs, or Proteasome inhibitors); concurrent use of bisphosphonates or receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor denosumab is not permitted; however, prior bisphosphonates or once-a-year intravenous bisphosphonate given for the treatment of osteoporosis is permitted
  • Ongoing treatment with with a dose >10 mg prednisone or equivalent per day at the time of randomization (or first study intervention administration in safety run-in cohort)
  • Women of or male participant with women of childbearing potential who do not agree to use a highly effective method of
  • Vaccination with a 4 weeks before the start of the study drug. Seasonal flu vaccines that do not contain live virus are permitted

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
337 participants (actual)

Study arms

  • Experimental
    Isatuximab, lenalidomide, and dexamethasone (ILd)

    Participants will receive isatuximab \[intravenous (IV) administration\] in combination with lenalidomide \[per os (PO) administration\] and dexamethasone \[IV on Day 1 of Cycle 1 for participants receiving isatuximab IV only and PO otherwise for subsequent cycles\] for 24 cycles followed by isatuximab monotherapy for 12 cycles for a total duration of 36 cycles. 1 cycle = 28 days. Participants may receive other treatments as pre-medication.

    Drug: Isatuximab SAR650984 · Drug: Lenalidomide · Drug: Dexamethasone · Drug: Montelukast or equivalent · Drug: Acetaminophen · Drug: Diphenhydramine or equivalent · Drug: Methylprednisolone or equivalent

  • Active comparator
    Lenalidomide and dexamethasone (Ld)

    Lenalidomide \[PO administration\] in combination with dexamethasone \[PO administration\] for 24 cycles. 1 cycle = 28 days

    Drug: Lenalidomide · Drug: Dexamethasone

Interventions

  • Pharmaceutical for: Solution for infusion Route of administration: Intravenous

    Also known as: Sarclisa

  • Pharmaceutical form: Capsules Route of administration: Oral

  • Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous

  • DrugMontelukast or equivalent

    Auxiliary Medicinal Product (AxMP)/pre-medication; ATC code: R03DC03; Pharmaceutical form: tablet; Route of administration: Oral;

  • AxMP/pre-medication ATC code: N02BE01 Pharmaceutical form: tablet/ampule/capsule; Route of administration: Intravenous (IV) or per os (PO)

  • DrugDiphenhydramine or equivalent

    AxMP/pre-medication ATC code: R06AA02 Pharmaceutical form: ampule; Route of administration: Intravenous

  • DrugMethylprednisolone or equivalent

    AxMP/pre-medication; ATC code: H02AB04; Pharmaceutical form: vial; Route of administration: Intravenous

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment-emergent adverse events (AEs) and serious adverse events- Safety Run-in Part

    Time frame: Up to approximately 63 months

  2. Plasma concentration of isatuximab during the treatment period - Safety Run-in Part

    Time frame: After first infusion from Cycle 1 Day 1 to Day 28 in safety run-in part

  3. Receptor density/receptor occupancy Safety Run-in Part

    Change in CD38 receptor occupancy from baseline

    Time frame: Baseline to Cycle 2 Day 1 (each cycle is 28 days)

  4. Progression-free survival (PFS) Randomized Phase 3 Part

    PFS defined as the time from randomization to MM (SLiM CRAB criteria) or other related conditions based on independent review committee (IRC) assessment according to 2014 International Myeloma Working Group (IMWG) criteria or death from any cause, whichever happens first

    Time frame: Up to approximately 114 months

Secondary outcomes

  1. Overall Response Rate (ORR)- Safety Run-in Part

    ORR defined as the proportion of participants with best overall response (BOR) recorded as partial response (PR) or better according to 2016 IMWG criteria

    Time frame: Up to approximately 63 months

  2. Duration of Response (DOR) - Safety Run-in Part

    DOR defined as the time from the date of the first response to date of first progressive disease (PD) or death, whichever happens first.

    Time frame: Up to approximately 63 months

  3. Minimal residual disease (MRD) negativity -Safety Run-in Part

    MRD negativity defined as the proportion of participants for whom MRD is negative in participants achieving very good partial response (VGPR) or above.

    Time frame: Up to approximately 36 months

  4. Time to diagnostic (SLiM CRAB) progression or death - Safety Run-in Part

    Time to diagnostic (SLiM CRAB) progression or death defined as the time from the date of the first study intervention administration to diagnosis of SLiM CRAB or other related conditions progression or death from any cause, whichever happens first.

    Time frame: Up to approximately 63 months

  5. Time to first-line treatment for multiple myeloma (MM) - Safety Run-in Part

    Time to first-line treatment for MM defined as the time from the date of the first study intervention administration to first-line treatment for MM.

    Time frame: Up to approximately 63 months

  6. Number of participants with anti-drug antibodies (ADA) against isatuximab- Safety Run-in Part

    Time frame: Up to approximately 63 months

  7. PFS in participants with chromosomal abnormalities - Safety Run-In Part

    Association of chromosomal abnormalities with survival outcomes

    Time frame: Up to approximately 63 months

  8. Overall Survival (OS) in participants with chromosomal abnormalities - Safety Run-In Part

    Association of chromosomal abnormalities with survival outcomes

    Time frame: Up to approximately 63 months

  9. Minimal residual disease (MRD) negativity - Randomized Phase 3 Part

    MRD negativity defined as the proportion Number of participants for whom MRD is negative in participants achieving VGPR or above.

    Time frame: Up to approximately 36 months

  10. Sustained MRD negativity - Randomized Phase 3 Part

    Sustained MRD negativity defined as the proportion of participants for whom MRD is negative during a minimum period of one year.

    Time frame: Up to approximately 36 months

  11. Second PFS (PFS2) - Randomized Phase 3 Part

    PFS2 defined as the time from the date of randomization to the date of first documentation of PD (as reported by the Investigator) after initiation of further treatment for MM or the date of death from any cause, whichever happens first

    Time frame: Up to approximately 144 months

  12. OS - Randomized Phase 3 Part

    OS defined as the time from date of randomization to death from any cause.

    Time frame: Up to approximately 114 months

  13. Complete response (CR) rate - Randomized Phase 3 Part

    Percentage of participants with a CR (or better \[stringent CR (sCR)\]) as defined by 2016 IMWG response criteria, assessed by an IRC based on central laboratory values.

    Time frame: Up to approximately 114 months

  14. Overall Response Rate (ORR) - Randomized Phase 3 Part

    ORR is defined as the proportion of participants with BOR recorded as PR or better according to the 2016 IMWG criteria, assessed by an IRC based on central laboratory values.

    Time frame: Up to approximately 114 months

  15. Duration of response (DOR) - Randomized Phase 3 Part

    DOR is defined as the time from the date of the first IRC determined response to the date of first IRC PD, or death, whichever happens first.

    Time frame: Up to approximately 114 months

  16. Time to diagnostic (SLiM CRAB) progression - Randomized Phase 3 Part

    Time to diagnostic (SLiM CRAB) progression defined as the time from randomization to the date of diagnosis of SLiM CRAB progression based on IRC assessment.

    Time frame: Up to approximately 114 months

  17. Time to biochemical progression - Randomized Phase 3 Part

    Time to biochemical progression defined as the time from randomization to the date of biochemical progression based on IRC assessment.

    Time frame: Up to approximately 114 months

  18. Time to first-line treatment for MM- Randomized Phase 3 Part

    Time to first-line treatment for MM defined as the time from randomization to first-line treatment for MM

    Time frame: Up to approximately 144 months

  19. PFS in participants with chromosomal abnormalities - Randomized Phase 3 Part

    Association of chromosomal abnormalities with survival outcomes.

    Time frame: Up to approximately 114 months

  20. OS in participants with chromosomal abnormalities - Randomized Phase 3 Part

    Association of chromosomal abnormalities with survival outcomes.

    Time frame: Up to approximately 144 months

  21. Number of participants with Treatment-emergent adverse events (AEs) and serious adverse events - Randomized Phase 3 Part

    Time frame: Up to approximately 144 months

  22. Plasma concentration of isatuximab (Ctrough)- Safety Run-in and Randomized Phase 3 Part

    Ctrough defined as concentration observed just before treatment administration during repeated dosing after IV administration

    Time frame: Baseline to Cycle 2 Day 1 (each cycle is 28 days)

  23. Concentration observed at the end of intravenous infusion.(Ceoi)- Safety Run-in Part

    Time frame: Day 1 of Cycle 1 to 4

  24. Number of participants with Incidence of anti-drug antibodies (ADA) against isatuximab- Randomized Phase 3 Part

    Time frame: Up to approximately 144 months

  25. European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 - Randomized Phase 3 Part

    The EORTC Multiple Myeloma Module (QLQ-C30) will be used to assess cancer-specific health related quality of life (HRQL), disease and treatment related symptoms and impact of symptoms. Mean change from baseline scores will be assessed, with responses ranging from 1=not at all to 4=very much or 1=very poor to 7=excellent; higher scores represent a better level of physical functioning

    Time frame: Baseline to follow-up (up to approximately 114 months)

  26. EORTC QLQ-MY20 - Randomized Phase 3 Part

    The EORTC Multiple Myeloma Module (QLQ-MY20) will be used to measure myeloma-specific HRQL, disease and treatment related symptoms and impact of symptoms. Mean change from baseline in scores will be assessed using a 4-point scale, with responses ranging from 1=not at all to 4=very much; higher scores represent better perspectives of the future and higher level of symptomatology

    Time frame: Baseline to follow-up (up to approximately 114 months)

  27. EQ-5D-5L - Randomized Phase 3 Part

    The EQ-5D-5L will be used to assess health status and health utility. Mean change from baseline scores will be assessed from 5 items, with responses ranging from 'no' to 'extreme problems'; health state utility values (HSUVs) are generated by multiplying the item scores by country specific value sets; health status is assessed via a VAS; higher scores = higher HSUV/health status

    Time frame: Baseline to follow-up (up to approximately 114 months)

  28. Randomized Phase 3: HRUPQ - Randomized Phase 3 Part

    Mean change from baseline in Health resource utilization and productivity questionnaire (HRUPQ) scores. HRUPQ will assess health care resource utilization of HRSM and the impact of high risk smoldering multiple myeloma (HRSMM) on employment/work; higher scores = greater impact on work/productivity, resources.

    Time frame: Baseline to follow-up (up to approximately 114 months)

  29. Patient's Qualitative Assessment of Treatment Version 2 (PQAT-v2) - Randomized Phase 3 Part

    PQAT-v2 will be used to assess participant-perceived advantages and disadvantages of treatment. Patient's qualitative assessment of treatment will be assessed using a 10 point VAS/NRS scale with response anchors of 'not beneficial at all' to 'extremely beneficial'; higher scores represent greater patient-perceived benefits of treatment

    Time frame: End of treatment (up to approximately 3 year)

07

Study locations

105 sites
  • UCLA Site Number : 8400010
    Los Angeles, California 90024, United States
  • Colorado Blood Cancer Institute Site Number : 8400007
    Denver, Colorado 80218, United States
  • Cancer Specialist of North Florida Site Number : 8400011
    Jacksonville, Florida 32256, United States
  • University of Miami Site Number : 8400012
    Miami, Florida 33136, United States
  • Dana Farber Cancer Institute Site Number : 8400001
    Boston, Massachusetts 02115, United States
  • Presbyterian Hospital Site Number : 8400015
    Charlotte, North Carolina 28204, United States
  • Novant Health Forsyth Medical Center Site Number : 8401015
    Winston-Salem, North Carolina 27103, United States
  • Tennessee Oncology Site Number : 8400006
    Nashville, Tennessee 37203, United States
  • ~University of Texas - MD Anderson Cancer Center Site Number : 8400002
    Houston, Texas 77030, United States
  • Investigational Site Number :0360008
    Liverpool, New South Wales 2170, Australia
  • Investigational Site Number :0360005
    Waratah, New South Wales 2298, Australia
  • Investigational Site Number :0360001
    Wollongong, New South Wales 2500, Australia
  • Investigational Site Number :0360002
    Fitzroy, Victoria 3065, Australia
  • Investigational Site Number :0360007
    Heidelberg West, Victoria 3081, Australia
  • Investigational Site Number :0360004
    Richmond, Victoria 3121, Australia
  • Investigational Site Number :0360006
    Nedlands, Western Australia 6009, Australia
  • Investigational Site Number :0760002
    São Paulo, São Paulo 04537-081, Brazil
  • Investigational Site Number :1240004
    Edmonton, Alberta T6G 1Z2, Canada
  • Investigational Site Number :1240005
    Moncton, New Brunswick E1C 6Z8, Canada
  • Investigational Site Number :1240001
    Montreal, Quebec H1T 2M4, Canada
  • Investigational Site Number :1560002
    Hangzhou, 310003, China
  • Investigational Site Number :1560003
    Hangzhou, 310003, China
  • Investigational Site Number :1560006
    Nanchang, 330006, China
  • Investigational Site Number :1560004
    Shanghai, 200032, China
  • Investigational Site Number :1560005
    Shenyang, 110022, China
  • Investigational Site Number :1560001
    Tianjin, 300020, China
  • Investigational Site Number : 2030004
    Brno, 62500, Czechia
  • Investigational Site Number : 2030005
    Hradec Králové, 50005, Czechia
  • Investigational Site Number : 2030002
    Olomouc, 77900, Czechia
  • Investigational Site Number : 2030003
    Ostrava - Poruba, 70852, Czechia
  • Investigational Site Number : 2030001
    Prague, 12808, Czechia
  • Investigational Site Number :2080001
    Aalborg, 9000, Denmark
  • Investigational Site Number :2080003
    Aarhus N, 8200, Denmark
  • Investigational Site Number :2080005
    Copenhagen, 2100, Denmark
  • Investigational Site Number :2080002
    Roskilde, 4000, Denmark
  • Investigational Site Number :2500009
    Ars-Laquenexy, 57085, France
  • Investigational Site Number :2500010
    Bayonne, 64109, France
  • Investigational Site Number :2500007
    Grenoble, 38043, France
  • Investigational Site Number :2500006
    La Roche-sur-Yon, 85925, France
  • Investigational Site Number :2500003
    Lille, 59037, France
  • Investigational Site Number :2500005
    Paris, 75012, France
  • Investigational Site Number :2500011
    Paris, 75013, France
  • Investigational Site Number :2500002
    Poitiers, 86021, France
  • Investigational Site Number :2500001
    Rennes, 35033, France
  • Investigational Site Number :2760001
    Hamburg, 20246, Germany
  • Investigational Site Number :2760002
    Heidelberg, 69120, Germany
  • Investigational Site Number :3000002
    Athens, 10676, Greece
  • Investigational Site Number :3000001
    Athens, 11528, Greece
  • Investigational Site Number :3000003
    Thessaloniki, PC 54007, Greece
  • Investigational Site Number :3480003
    Budapest, 1083, Hungary
  • Investigational Site Number :3480001
    Budapest, 1097, Hungary
  • Investigational Site Number :3480002
    Debrecen, 4032, Hungary
  • Investigational Site Number :3480004
    Kaposvár, 7400, Hungary
  • Investigational Site Number :3720001
    Dublin, Dublin, Ireland
  • Investigational Site Number :3720002
    Dublin, Dublin, Ireland
  • Investigational Site Number :3720003
    Dublin, Dublin, Ireland
  • Investigational Site Number :3760004
    Ashdod, 7747629, Israel
  • Investigational Site Number :3760001
    Jerusalem, 91031, Israel
  • Investigational Site Number :3760002
    Jerusalem, 91120, Israel
  • Investigational Site Number :3760005
    Petah Tikva, 49100, Israel
  • Investigational Site Number :3760006
    Ramat Gan, 5265601, Israel
  • Investigational Site Number :3760003
    Tel Aviv, 64239, Israel
  • Investigational Site Number :3800006
    Meldola, Forlì-Cesena 47014, Italy
  • Investigational Site Number :3800001
    Rozzano, Milano 20089, Italy
  • Investigational Site Number :3800005
    Ancona, 60032, Italy
  • Investigational Site Number :3800003
    Bologna, 40138, Italy
  • Investigational Site Number :3800002
    Terni, 05100, Italy
  • Investigational Site Number :3920002
    Nagoya, Aichi-ken 467-8602, Japan
  • Investigational Site Number :3920006
    Kamogawa-shi, Chiba 296-8602, Japan
  • Investigational Site Number :3920008
    Maebashi, Gunma 371-8511, Japan
  • Investigational Site Number :3920005
    Higashiibaraki-gun, Ibaraki 311-3193, Japan
  • Investigational Site Number :3920003
    Okayama, Okayama-ken 701-1192, Japan
  • Investigational Site Number :3920009
    Sunto-gun, Shizuoka 411-8777, Japan
  • Investigational Site Number :3920001
    Shibuya-ku, Tokyo 150-8935, Japan
  • Investigational Site Number :4400001
    Vilnius, 08661, Lithuania
  • Investigational Site Number :5540004
    Christchurch, Canterbury, New Zealand
  • Investigational Site Number :5540001
    Hamilton, Waikato Region 3204, New Zealand
  • Investigational Site Number :5780002
    Bergen, 5021, Norway
  • Investigational Site Number :5780001
    Oslo, 0450, Norway
  • Investigational Site Number :6160006
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-168, Poland
  • Investigational Site Number :6160002
    Lodz, Lódzkie 93-510, Poland
  • Investigational Site Number :6160008
    Gdansk, Pomeranian Voivodeship 80-214, Poland
  • Investigational Site Number :6160005
    Chorzów, Silesian Voivodeship 41-500, Poland
  • Investigational Site Number :4100004
    Gangnam-gu, Seoul-teukbyeolsi 06351, South Korea
  • Investigational Site Number :4100003
    Seoul, Seoul-teukbyeolsi 03080, South Korea
  • Investigational Site Number :4100001
    Seoul, Seoul-teukbyeolsi 03722, South Korea
  • Investigational Site Number :4100002
    Seoul, 06591, South Korea
  • Investigational Site Number :7240004
    Barcelona, Barcelona [Barcelona] 08036, Spain
  • Investigational Site Number :7240001
    Barcelona, Barcelona [Barcelona] 08041, Spain
  • Investigational Site Number :7240006
    Pamplona, Navarre 31008, Spain
  • Investigational Site Number :7240002
    Valencia, Valenciana, Comunidad 46017, Spain
  • Investigational Site Number :7240005
    Madrid, 28041, Spain
  • Investigational Site Number :7240007
    Salamanca, 37007, Spain
  • Investigational Site Number :7240003
    Zaragoza, 50009, Spain
  • Investigational Site Number :7520001
    Gothenburg, 413 45, Sweden
  • Investigational Site Number :7520003
    Helsingborg, 251 87, Sweden
  • Investigational Site Number : 7920005
    Ankara, 06010, Turkey (Türkiye)
  • Investigational Site Number : 7920001
    Ankara, 06620, Turkey (Türkiye)
  • Investigational Site Number : 7920004
    Istanbul, 34214, Turkey (Türkiye)
  • Investigational Site Number : 7920002
    Istanbul, 34390, Turkey (Türkiye)

Showing the first 100 of 105 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Oct 2030, 123 months after the start.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 123 months is above that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2020
First posted
Feb 17, 2020
StartActual
Jun 16, 2020
Primary completionEst.
Oct 14, 2030
CompletionEst.
Oct 21, 2033
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04270409
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 17, 2020
Start date
Jun 16, 2020
Primary completion
Oct 14, 2030 (estimated)
Completion
Oct 21, 2033 (estimated)
Last update
Dec 12, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion